5-HT radioligands for human brain imaging with PET and SPECT

Medicinal Research Reviews

Volumn 33, Issue 1, 2013, Pages 54-111

  Paterson, Louise M ^a   Kornum, Birgitte R ^b   Nutt, David J ^a   Pike, Victor W ^c   Knudsen, Gitte M ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT; PET; Radioligand; SPECT

Indexed keywords

(4 FLUORANYLMETHYL) N [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] N PYRIDIN 2 YLCYCLOHEXANE 1 CARBOXAMIDE F 18; (O METHYL) 2 [4 [4 (2 METHOXYPHENYL) 6 PIPERAZIN 1 YL]BUTYL] 4 METHYL 1,2,4 TRIAZINE 3,5(2H,4H)DIONE F 18; 1 (AZEPAN 1 YL) 4 [4 (2 METHOXYPHENYL]PIPERAZIN 1 YL] 2 PHENYLBUTAN 1 ONE C 11; 3 CHLORO 4 FLUOROPHENYL [4 FLUORO 4[[(5 METHYL PYRIMIDIN 2 YLMETHYL) AMINO]METHYL] PIPERIDIN 1 YL] METHANONE F 18; 4 FLUORANYL N [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] N PYRIDIN 2 YLBENZAMIDE F 18; [O METHYL] 2 [4 [4 (2 METHYOXYPHENYL)PIPERAZIN 1 YL]BUTYL] 4 METHYL 1,2,4 TRIAZINE 3,5(2H,4H)DIONE C 11; ALTANSERIN F 18; AZ 10419369 C 11; DEUTEROALTANSERIN F 18; DR 446 C 11; GSK 215083 C 11; GSK 224558 C 11; KETANSERIN C 11; MDL 100907 C 11; MDL 72222 C 11; N [2 [1 [4 (2 METHOXYPHENYL) PIPERAZINYL]ETHYL]] N [2 (6 FLUOROPYRIDINYL)] CYCLOHEXANECARBOXAMIDE F 18; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDINYL) 2 BICYCLO [2,2,2]OCTANECARBOXAMIDE C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; P 943 C 11; R 91150 I 123; RADIOLIGAND; ROBALZOTAN C 11; RP 62203 F 18; SB 207145 C 11; SB 207710 I 123; SEROTONIN; SEROTONIN TRANSPORTER; SETOPERONE F 18; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 060 C 11;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CEREBELLUM; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HUMAN; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84871088261     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20245     Document Type: Article

References (419)

1. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083.
2. Monti JM. The role of dorsal raphe nucleus serotonergic and non-serotonergic neurons, and of their receptors, in regulating waking and rapid eye movement (REM) sleep. Sleep Med Rev 2010;14:319-327.
3. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ. Serotonin and human cognitive performance. Curr Pharm Des 2006;12:2473-2486.
4. 6 receptors in learning and memory. Trends Pharmacol Sci 2008;29:482-492.
5. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
6. Stein DJ, Stahl S. Serotonin and anxiety: Current models. Int Clin Psychopharmacol 2000;15:S1-S6.
7. Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog Brain Res 2008;172:117-140.
8. Garcia-Alloza M, Gil-Bea FJ, Ez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005;43:442-449.
9. Michelsen KA, Prickaerts J, Steinbusch HW. The dorsal raphe nucleus and serotonin: Implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res 2008;172:233-264.
10. Jobe PC, Dailey JW, Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 1999;13:317-356.
11. Veltman DJ, Ruhe HG, Booij J. Investigating serotonergic function using positron emission tomography: Overview and recent findings. Curr Pharm Des 2010;16:1979-1989.
12. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
13. Bockaert J, Claeysen S, Becamel C, Dumuis A, Marin P. Neuronal 5-HT metabotropic receptors: Fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res 2006;326:553-572.
14. Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007;59:360-417.
15. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008;195:198-213.
16. Wagner HN, Jr, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ. Imaging dopamine receptors in the human brain by positron tomography. Science 1983;221:1264-1266.
17. Kaye WH, Frank GK, Bailer UF, Henry SE, Meltzer CC, Price JC, Mathis CA, Wagner A. Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies. Physiol Behav 2005;85:73-81.
18. Fowler JS, Ding YS, Volkow ND. Radiotracers for positron emission tomography imaging. Semin Nucl Med 2003;33:14-27.
19. Volkow ND, Fowler JS, Wang GJ. Positron emission tomography and single-photon emission computed tomography in substance abuse research. Semin Nucl Med 2003;33:114-128.
20. Smith DF, Jakobsen S. Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol 2009;19:611-628.
21. 18)2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol 1979;6:371-388.
22. 18F]fluorodeoxyglucose. J Comput Assist Tomogr 1983;7:590-598.
23. Hasselbalch SG, Knudsen GM, Videbaek C, Pinborg LH, Schmidt JF, Holm S, Paulson OB. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999;48:1915-1921.
24. 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement 2008;4:S29-S36.
25. Kessler RM, Goble JC, Bird JH, Girton ME, Doppman JL, Rapoport SI, Barranger JA. Measurement of blood-brain barrier permeability with positron emission tomography and [68Ga]EDTA. J Cereb Blood Flow Metab 1984;4:323-328.
26. Josserand V, Pelerin H, de Bruin B, Jego B, Kuhnast B, Hinnen F, Duconge F, Boisgard R, Beuvon F, Chassoux F, Dumas-Duport C, Ezan E, Dolle F, Mabondzo A, Tavitian B. Evaluation of drug penetration into the brain: A double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J Pharmacol Exp Ther 2006;316:79-86.
27. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, Van Oostrom JC, Portman A, Leenders KL. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 2008;115:1001-1009.
28. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langstrom B, Knudsen GM, Hammarlund-Udenaes M. Species differences in blood-brain barrier transport of three PET radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009;37:635-643.
29. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000;20:423-451.
30. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM. Measuring endogenous 5-HT release by emission tomography: Promises and pitfalls. J Cereb Blood Flow Metab 2010;30:1682-1706.
31. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
32. 11)C]DASB PET imaging study. Am J Psychiatry 2001;158:1843-1849.
33. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007;61:1081-1089.
34. 1A receptor binding in people with panic disorder: Positron emission tomography study. Br J Psychiatry 2008;193:229-234.
35. 11)C]MDL 100, 907. Am J Psychiatry 2006;163:1580-1587.
36. 1A) receptors in the rat hippocampus. Neurobiol Aging 2011;32:103-114.
37. 11C]-raclopride. Synapse 2004;52:188-208.
38. 11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 2010;333:533-539.
39. Pike VW. PET radiotracers: Crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009;30:431-440.
40. 18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab 2003;23:985-996.
41. Lanfumey L, Hamon M. 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:1-10.
42. Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627-635.
43. 1A receptors in vivo. Prog Med Chem 2001;38:189-247.
44. 1A) receptors in the central nervous system. Eur J Nucl Med 2001;28:113-129.
45. 1A) receptors and uses thereof. Drug Discov Today 2007;12:748-756.
46. 18]MPPF in the nonhuman primate. Synapse 2011;65:592-600.
47. 1A) receptor agonist, as a radioligand for PET neuroimaging. Eur J Nucl Med Mol Imaging 2010;37:594-605.
48. 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med 2008;49:587-596.
49. 1A receptors in rat brain. Synapse 1994;18:359-366.
50. 123I]p-MPPI in nonhuman primates. Synapse 1996;24:273-281.
51. 1A receptor ligands. J Med Chem 1998;41:157-166.
52. 18F]MPPF in rats. Eur J Pharmacol 2000;407:273-280.
53. 1A) receptor derived from desmethyl-WAY-100635 (DWAY). Eur J Nucl Med Mol Imaging 2002;29:82-87.
54. 1A receptor imaging agent. Chem Lett 2006;35:1304-1305.
55. 1A receptor imaging agent. Appl Radiat Isot 2007;65:287-292.
56. 1A receptor ligand and labelled with Tc-99m-nitrido core. J Labl Compd Radiopharm 2008;51:347-351.
57. 1A receptor imaging agent. Bull Korean Chem Soc 2009;30:1107-1112.
58. 1A receptor imaging. Sci China Ser B Chem 2009;52:590-598.
59. 1A receptor antagonist. Behav Brain Res 1996;73:337-353.
60. Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology 2006;188:244-251.
61. 1A receptors by [3H]WAY 100635 in the mouse. Eur J Pharmacol 1994;271:505-514.
62. 11C]way-100635. Brain Res 1997;745:96-108.
63. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 1997;30:565-574.
64. 1A receptors with positron emission tomography. Life Sci 1994;55:PL403-PL407.
65. 11C]WAY-100635. Eur J Pharmacol 1995;283:R1-R3.
66. 11C]WAY-100635, in monkey and human plasma by HPLC: Comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl Med Biol 1996;23:627-634.
67. 11C]WAY-100635-Explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl Med Biol 1998;25:215-223.
68. 1A) receptors in normal male volunteers: Normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 2002;15:620-632.
69. 1A receptor binding in medication-free bipolar depression. Biol Psychiatry 2009;66:223-230.
70. 1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry 2007;61:1090-1099.
71. 11C]WAY-100635 for PET. Neuroimage 1998;8:426-440.
72. 1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab 2005;25:785-793.
73. 11)C]WAY-100635-considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab 2007;27:185-195.
74. 1A receptor sites in the human brain with the hypotime method: Theory and normal values. J Nucl Med 2009;50:1229-1236.
75. 11C]CPC-222. Nucl Med Commun 1997;18:1130-1134.
76. 1A) receptors with PET: WAY-100635 and analogues. Nucl Med Biol 2000;27:463-466.
77. 11C](R)-(-)-RWAY. Synapse 2006;60:510-520.
78. 1A receptors with PET. Eur J Nucl Med Mol Imaging 2007;34:1670-1682.
79. 11C](R)-(-)-RWAY: Radiometabolite(s) likely confound brain measurements. Synapse 2007;61:469-477.
80. 1A receptors in vitro and in vivo. Eur J Nucl Med 1998;25:338-346.
81. 11)C]WAY-100635 in the human brain. J Nucl Med 2002;43:292-303.
82. 11C]desmethyl-WAY-100635. Appl Radiat Isot 2005;62:721-727.
83. 1A receptors in living monkey. Nucl Med Biol 2001;28:177-185.
84. 1A receptor imaging with PET. Bioorg Med Chem 2003;11:2769-2782.
85. 1A receptor radioligand behavior in vivo. Mol Imaging Biol 2004;6:17-26.
86. 1A receptors in humans. Synapse 1997;25:147-154.
87. 1A receptors in animal and human brain. Neuropharmacology 2007;52:695-707.
88. 1A receptor antagonist: [3H]p-MPPF. Synapse 1996;23:344-346.
89. 18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol 1998;25:343-350.
90. 18F]MPPF. J Nucl Med 2000;41:1830-1835.
91. 18)f]p-MPPF. Nucl Med Biol 2000;27:473-476.
92. 18F]MPPF uptake in rat brain and peripheral tissues: MicroPET and ex vivo studies. Eur J Nucl Med Mol Imaging 2008;35:2256-2266.
93. 18F]MPPF-PET study. Brain 2004;127:900-913.
94. Truchot L, Costes SN, Zimmer L, Laurent B, Le Bars D, Thomas-Anterion C, Croisile B, Mercier B, Hermier M, Vighetto A, Krolak-Salmon P. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology 2007;69:1012-1017.
95. 18F-MPPF-PET study. Cephalalgia 2008;28:1282-1291.
96. Demarquay G, Lothe A, Royet J, Costes N, Mick G, Mauguiere F, Ryvlin P. Brainstem changes in 5-HT1A receptor availability during migraine attack. Cephalalgia 2011;31:84-94.
97. 18F]MPPF PET study. Brain 2008;131:2765-2782.
98. 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med 2005;46:1980-1989.
99. 18F-MPPF PET in healthy humans: A reliability study. J Nucl Med 2007;48:1279-1288.
100. 18)F]MPPF binding potential in the dorsal raphe nucleus after a single oral dose of fluoxetine: A positron-emission tomography study in healthy volunteers. Biol Psychiatry 2008;63:1135-1140.
101. 18)F]MPPF binding. Synapse 2002;46:108-115.
102. 18)F] MPPF positron emission tomography study. Biol Psychiatry 2004;56:587-591.
103. 18F]MPPF PET study in narcolepsy. Neuroimage 2006;30:341-348.
104. 18F]DMPPF, a new 5-HT1A ligand for PET, in rats. Nucl Med Biol 2006;33:667-675.
105. Lang L, Jagoda E, Schmall B, Vuong BK, Adams HR, Nelson DL, Carson RE, Eckelman WC. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem 1999;42:1576-1586.
106. 18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl Med Biol 2000;27:493-497.
107. 18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635. Bioorg Med Chem 2006;14:3737-3748.
108. Toczek MT, Carson RE, Lang L, Ma Y, Spanaki MV, Der MG, Fazilat S, Kopylev L, Herscovitch P, Eckelman WC, Theodore WH. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003;60:749-756.
109. Giovacchini G, Toczek MT, Bonwetsch R, Bagic A, Lang L, Fraser C, Reeves-Tyer P, Herscovitch P, Eckelman WC, Carson RE, Theodore WH. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med 2005;46:1128-1135.
110. Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagic A, Luckenbaugh DA, Drevets WC, Theodore WH. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007;62:1258-1264.
111. 18F-FDG PET in MRI-negative temporal lobe epilepsy. Epilepsia 2009;50:234-239.
112. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Herscovitch P, Charney DS, Drevets WC. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004;24:589-591.
113. Bonne O, Bain E, Neumeister A, Nugent AC, Vythilingam M, Carson RE, Luckenbaugh DA, Eckelman W, Herscovitch P, Drevets WC, Charney DS. No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. Am J Psychiatry 2005;162:383-385.
114. 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. J Nucl Med 2006;47:345-353.
115. 18)F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain. J Nucl Med 2007;48:1154-1161.
116. 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. J Nucl Med 2006;47:1697-1706.
117. Jerning E, Svantesson GT, Mohell N. Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist. Eur J Pharmacol 1998;360:219-225.
118. 11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor. Nucl Med Biol 1999;26:159-164.
119. 11)C]NAD-299, a radioligand for visualisation of the 5-HT(1A) receptor. Nucl Med Biol 2002;29:39-45.
120. 11C]2-4-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]butyl-4-methyl-2H-[1, 2, 4]triazine-3, 5-dione: A novel 5-HT1A receptor agonist positron emission tomography ligand. J Med Chem 2006;49:125-134.
121. 11C] 2-4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl-4-methyl-2H-[1, 2, 4]-triazi ne-3, 5-dione: A novel agonist 5-HT1A receptor PET ligand. Bioorg Med Chem Lett 2006;16:2101-2104.
122. 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1, 2, 4-triazine -3, 5(2H, 4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 2007;34:1050-1060.
123. 11)C]CUMI-101: A serotonin 1A receptor agonist positron emission tomography radiotracer. J Cereb Blood Flow Metab 2011;31:243-249.
124. Palner M, Underwood MD, Kumar DJ, Arango V, Knudsen GM, Mann JJ, Parsey RV. Ex vivo evaluation of the serotonin 1A receptor partial agonist [(3)H]CUMI-101 in awake rats. Synapse 2010.
125. 11C-CUMI-101, an agonist PET radiotracer. J Nucl Med 2010;51:1892-1900.
126. Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B. High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity. J Med Chem 2007;50:5024-5033.
127. Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol 2009;156:338-353.
128. Lu S, Liow JS, Zoghbi SS, Hong J, Innis RB, Pike VW. Evaluation of [C]S14506 and [F]S14506 in rat and monkey as agonist PET radioligands for brain 5-HT(1A) receptors. Curr Radiopharm 2010;3:9-18.
129. Domenech T, Beleta J, Palacios JM. Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1997;356:328-334.
130. Bonaventure P, Schotte A, Cras P, Leysen JE. Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand. Recept Channels 1997;5:225-230.
131. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1988;1:1309-1311.
132. Ruf BM, Bhagwagar Z. The 5-HT1B receptor: A novel target for the pathophysiology of depression. Curr Drug Targets 2009;10:1118-1138.
133. Olivier B, van Oorschot R. 5-HT1B receptors and aggression: A review. Eur J Pharmacol 2005;526:207-217.
134. Sari Y. Serotonin1B receptors: From protein to physiological function and behavior. Neurosci Biobehav Rev 2004;28:565-582.
135. 11C]AZ10419369 binding to 5-HT1B receptors in the primate brain. Synapse 2010;64:573-577.
136. 11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 2008;41:1075-1085.
137. 11)C]AZ10419369 binding to 5-HT(1B) receptors in human brain. J Cereb Blood Flow Metab 2011;31:113-123.
138. Maier DL, Sobotka-Briner C, Ding M, Powell ME, Jiang Q, Hill G, Heys JR, Elmore CS, Pierson ME, Mrzljak L. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: In vitro characterization and in vivo receptor occupancy. J Pharmacol Exp Ther 2009;330:342-351.
139. 11)C]P943 in humans. J Cereb Blood Flow Metab 2010;30:196-210.
140. 11C]P943. Nucl Med Biol 2010;37:205-214.
141. Varnas K, Hall H, Bonaventure P, Sedvall G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743. Brain Res 2001;915:47-57.
142. Hu J, Henry S, Gallezot JD, Ropchan J, Neumaier JF, Potenza MN, Sinha R, Krystal JH, Huang Y, Ding YS, Carson RE, Neumeister A. Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry 2010;67:800-803.
143. Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF, Neumeister A. Reduced ventral striatal/ventral pallidal serotonin(1B) receptor binding potential in major depressive disorder. Psychopharmacology 2011;213:547-553.
144. 1E) serotonin receptors in human brain. Neurosci Lett 1992;136:223-226.
145. Wainscott DB, Krushinski JH, Jr, Audia JE, Schaus JM, Zgombick JM, Lucaites VL, Nelson DL. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch Pharmacol 2005;371:169-177.
146. Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, Diener HC. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-A randomised proof-of-concept trial. Cephalalgia 2010;30:1170-1178.
147. Ward SE, Watson JM. Recent advances in the discovery of selective and non-selective 5-HT(1D) receptor ligands. Curr Topics Med Chem 2010;10:479-492.
148. Lucaites VL, Krushinski JH, Schaus JM, Audia JE, Nelson DL. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch Pharmacol 2005;371:178-184.
149. Rosel P, Arranz B, San L, Vallejo J, Crespo JM, Urretavizcaya M, Navarro MA. Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 2000;99:173-181.
150. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987;21:123-139.
151. Cornea-Hebert V, Riad M, Wu C, Singh SK, Descarries L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 1999;409:187-209.
152. 11)C]M100907. Synapse 2000;38:421-431.
153. Leysen JE. 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:11-26.
154. Gonzalez-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci 2009;32:225-232.
155. Sargent T, 3rd, Budinger TF, Braun G, Shulgin AT, Braun U. An iodinated catecholamine congener for brain imaging and metabolic studies. J Nucl Med 1978;19:71-76.
156. Sargent T, Kalbhen DA, Shulgin AT, Braun G, Stauffer H, Kusubov N. In vivo human pharmacodynamics of the psychodysleptic 4-BR-2, 5-dimethoxyphenylisopropylamine labelled with 'BRor 'BR. Neuropharmacology 1975;14:165-174.
157. 125I]-1-(2, 5-dimethoxy-4-iodophenyl)-2-amino-propane: An iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors. J Med Chem 1988;31:5-7.
158. 125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. J Pharmacol Exp Ther 1990;255:843-857.
159. 125I]-DOI, a selective psychotomimetic radioligand. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:573-581.
160. 123I]DOI, A 5HT(2A/2C) serotonin agonist. Nucl Med Biol 2002;29:575-583.
161. 11C]MSP: New selective 5-HT2A receptor radiopharmaceuticals for in vivo studies of neuronal 5-HT2 serotonin receptors. Synthesis, in vitro binding study with unlabelled analogues and preliminary in vivo evaluation in mice. Life Sci 1998;63:2001-2013.
162. 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects. Eur J Nucl Med 1997;24:119-124.
163. 123I]R93274 as a SPECT radiotracer for imaging 5-HT2A receptors. Eur J Pharmacol 1997;321:285-293.
164. Mertens J, Terriere D, Sipido V, Gommeren W, Janssen PMF, Leysen JE. Radiosynthesis of a new radioiodinated ligand for serotonin-5HT2-receptors, a promising tracer for gamma-emission tomography. J Labl Compd Radiopharm 1994;34:795-806.
165. Terriere D, Janssen PM, Gommeren W, Gysemans M, Mertens JJ, Leysen JE. Evaluation of radioiodo-4-amino-N-[1-[3-(4-fluorophenoxy)-propyl]-4-methyl-4-piperidinyl]-5-iodo-2-methoxybenzamide as a potential 5HT2 receptor tracer for SPE(C)T. Nucl Med Biol 1995;22:1005.
166. 123I-R91150 in healthy volunteers: Part 1-Pseudoequilibrium interval and quantification methods. J Nucl Med 2006;47:919-928.
167. 123I-R91150 in healthy volunteers: Part 2-Ketanserin displacement. J Nucl Med 2006;47:929-937.
168. Travis MJ, Busatto GF, Pilowsky LS, Mulligan R, Acton PD, Gacinovic S, Mertens J, Terriere D, Costa DC, Ell PJ, Kerwin RW. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br J Psychiatry 1998;173:236-241.
169. Jones HM, Travis MJ, Mulligan R, Visvikis D, Gacinovic S, Ell PJ, Kerwin RW, Pilowsky LS. In vivo serotonin 5-HT(2A) receptor occupancy and quetiapine. Am J Psychiatry 2000;157:148.
170. Jones HM, Travis MJ, Mulligan R, Bressan RA, Visvikis D, Gacinovic S, Ell PJ, Pilowsky LS. In vivo 5-HT2A receptor blockade by quetiapine: An R91150 single photon emission tomography study. Psychopharmacology 2001;157:60-66.
171. Versijpt J, Van Laere KJ, Dumont F, Decoo D, Vandecapelle M, Santens P, Goethals I, Audenaert K, Slegers G, Dierckx RA, Korf J. Imaging of the 5-HT2A system: Age-, gender-, and Alzheimer's disease-related findings. Neurobiol Aging 2003;24:553-561.
172. Audenaert K, Van Laere K, Dumont F, Slegers G, Mertens J, van Heeringen C, Dierckx RA. Decreased frontal serotonin 5-HT 2a receptor binding index in deliberate self-harm patients. Eur J Nucl Med 2001;28:175-182.
173. van Heeringen C, Audenaert K, Van Laere K, Dumont F, Slegers G, Mertens J, Dierckx RA. Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. J Affect Disord 2003;74:149-158.
174. Audenaert K, Van Laere K, Dumont F, Vervaet M, Goethals I, Slegers G, Mertens J, van Heeringen C, Dierckx RA. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med 2003;44:163-169.
175. Goethals I, Vervaet M, Audenaert K, Jacobs F, Ham H, Van de Wiele C, Vandecapelle M, Slegers G, Dierckx R, van Heeringen C. Differences of cortical 5-HT2A receptor binding index with SPECT in subtypes of anorexia nervosa: Relationship with personality traits? J Psychiatr Res 2007;41:455-458.
176. 123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: Influence of age and gender in healthy subjects. Eur J Nucl Med 1998;25:1617-1622.
177. 18]R91150 as a serotonin 5-HT2A receptor antagonist for PET. J Labl Compd Radiopharm 2009;52:13-22.
178. Fu X, Tan PZ, Kula NS, Baldessarini R, Tamagnan G, Innis RB, Baldwin RM. Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT2A ligands for PET or SPECT brain imaging. J Med Chem 2002;45:2319-2324.
179. 123I]-(4-fluorophenyl) 1-[2-(4-iodophenyl)ethyl]piperidin-4-ylmethanone for visualization of the 5-HT2A receptor with SPECT. Appl Radiat Isot 2005;62:737-743.
180. 123](4-fluorophenyl) 1-[2-(2(2-iodophenyl)-ethyl]piperidin-4-ylmethanone, a potential 5-HT2A-antagonist for SPECT brain imaging. J Labl Compd Radiopharm 2004;47:591-598.
181. 123)-(4-fluorophenyl)(1-(3-iodophenethyl)piperidin-4-yl) methanone as a potential SPECT-tracer for the serotonin 5-HT2A receptor. J Labl Compd Radiopharm 2007;50:183-188.
182. 123)I]-3-I-CO as a potential SPECT tracer for the serotonin 5-HT(2A) receptor. Nucl Med Biol 2008;35:861-867.
183. Baron JC, Samson Y, Comar D, Crouzel C, Deniker P, Agid Y. In vivo study of central serotoninergic receptors in man using positron tomography. Rev Neurol 1985;141:537-545.
184. 18F]fluoroethylketanserin and PET. Neurosci Lett 1991;123:23-26.
185. Lyon RA, Titeler M, Frost JJ, Whitehouse PJ, Wong DF, Wagner HN, Jr, Dannals RF, Links JM, Kuhar MJ. 3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex. J Neurosci 1986;6:2941-2949.
186. Frost JJ, Smith AC, Kuhar MJ, Dannals RF, Wagner HN, Jr. In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 1987;40:987-995.
187. Wong DF, Wagner HN, Jr, Dannals RF, Links JM, Frost JJ, Ravert HT, Wilson AA, Rosenbaum AE, Gjedde A, Douglass KH, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984;226:1393-1396.
188. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 2000;66:2455-2464.
189. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 1993;110:265-272.
190. Nordstrom AL, Farde L, Halldin C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 1993;110:365-367.
191. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449.
192. Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, Szymanski S, Wilson PD, Howard DR, Wong DF. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100, 907 measured by positron emission tomography. Neuropsychopharmacology 1997;17:175-185.
193. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology 2007;190:241-249.
194. 11C]methyl)-2-Br-LSD: A radioligand for positron emission tomographic studies of serotonin 5-HT2 receptors. Int J Rad Appl Instrum B 1989;16:697-704.
195. 11C]-methyl)-2-Br-LSD. Synapse 1987;1:393-398.
196. Burris KD, Breeding M, Sanders-Bush E. (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther 1991;258:891-896.
197. 18F]setoperone: A new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol 1988;147:73-82.
198. 18F-labeled setoperone. J Neurochem 1990;54:1744-1754.
199. Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: Implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154:1525-1529.
200. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. Binding of antipsychotic drugs to cortical 5-HT2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998;155:505-508.
201. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818-825.
202. 18F]setoperone. Brain 1993;116:497-510.
203. 18F-fluorosetoperone. Cephalalgia 1995;15:104-108; discussion 177.
204. Vera P, Zilbovicius M, Chabriat H, Amarenco P, Kerdraon J, Menard JF, Amarenco G, Bousser MG, Rancurel G, Samson Y. Post-stroke changes in cortical 5-HT2 serotonergic receptors. J Nucl Med 1996;37:1976-1981.
205. Massou JM, Trichard C, Attar-Levy D, Feline A, Corruble E, Beaufils B, Martinot JL. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology 1997;133:99-101.
206. 18F]setoperone PET imaging study. Am J Psychiatry 1999;156:1029-1034.
207. 18F]setoperone. Biol Psychiatry 2005;57:1004-1010.
208. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L. Fluorine-18-altanserin: A radioligand for the study of serotonin receptors with PET: Radiolabeling and in vivo biologic behavior in rats. J Nucl Med 1991;32:2266-2272.
209. Biver F, Goldman S, Luxen A, Monclus M, Forestini M, Mendlewicz J, Lotstra F. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med 1994;21:937-946.
210. 18F]altanserin: Results in young normal controls. J Cereb Blood Flow Metab 1995;15:787-797.
211. 18F]altanserin in human and rodent. Nucl Med Biol 1999;26:601-608.
212. 18)F] altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons. Synapse 2001;41:1-10.
213. 18)F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans. Synapse 2001;41:11-21.
214. 18F]altanserin. J Nucl Med 2000;41:234-241.
215. 18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging 2007;34:910-915.
216. 18F]altanserin to serotonin type 2A receptors in aging: Persistence of effect after partial volume correction. Brain Res 1998;813:167-171.
217. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-HT(2A) receptors in midlife than in late life. Am J Psychiatry 2002;159:430-435.
218. 18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: Normative data and relationship to physiological and demographic variables. Neuroimage 2004;21:1105-1113.
219. 18F]-altanserin PET study. Eur J Nucl Med Mol Imaging 2009;36:287-293.
220. 18F]altanserin positron emission tomography. Neuropsychopharmacology 2004;29:2235-2241.
221. 18F]altanserin positron emission tomography. Biol Psychiatry 2004;55:217-224.
222. Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, Skovira K. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 2002;52:896-906.
223. Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L, McConaha CW, Henry SE, Brooks-Achenbach S, Barbarich NC, Kaye WH. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: Relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 2004;29:1143-1155.
224. Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, Bolwig TG, Knudsen GM. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 2005;8:391-401.
225. Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, Mulsant BH, Ben-Eliezer D, Lopresti B, DeKosky ST, Reynolds CF, 3rd. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 1999;156:1871-1878.
226. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, Waldemar G, Knudsen GM. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1830-1838.
227. Haugbol S, Pinborg LH, Regeur L, Hansen ES, Bolwig TG, Nielsen FA, Svarer C, Skovgaard LT, Knudsen GM. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. Int J Neuropsychopharmacol 2007;10:245-252.
228. Hurlemann R, Boy C, Meyer PT, Scherk H, Wagner M, Herzog H, Coenen HH, Vogeley K, Falkai P, Zilles K, Maier W, Bauer A. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol 2005;210:519-523.
229. Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, Bauer A. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology 2008;195:579-590.
230. Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, Baare W, Svarer C, Madsen J, Lublin H, Knudsen GM, Glenthoj BY. Cortical and subcortical 5-HT(2A) receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 2008;33:2435-2441.
231. Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg LH, Baare WF, Svarer C, Lublin H, Knudsen GM, Glenthoj B. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology 2011;213:583-592.
232. Frokjaer VG, Mortensen EL, Nielsen FA, Haugbol S, Pinborg LH, Adams KH, Svarer C, Hasselbalch SG, Holm S, Paulson OB, Knudsen GM. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 2008;63:569-576.
233. Frokjaer VG, Vinberg M, Erritzoe D, Baare W, Holst KK, Mortensen EL, Arfan H, Madsen J, Jernigan TL, Kessing LV, Knudsen GM. Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. Neuropsychopharmacology 2010;35:1129-1137.
234. Erritzoe D, Frokjaer VG, Haugbol S, Marner L, Svarer C, Holst K, Baare WF, Rasmussen PM, Madsen J, Paulson OB, Knudsen GM. Brain serotonin 2A receptor binding: Relations to body mass index, tobacco and alcohol use. Neuroimage 2009;46:23-30.
235. Frokjaer VG, Erritzoe D, Madsen J, Paulson OB, Knudsen GM. Gender and the use of hormonal contraception in women are not associated with cerebral cortical 5-HT 2A receptor binding. Neuroscience 2009;163:640-645.
236. Pinborg LH, Arfan H, Haugbol S, Kyvik KO, Hjelmborg JV, Svarer C, Frokjaer VG, Paulson OB, Holm S, Knudsen GM. The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined. Neuroimage 2008;40:1175-1180.
237. 18F]deuteroaltanserin and PET: Feasibility of a constant infusion paradigm. Nucl Med Biol 2000;27:715-722.
238. 18F]deuteroaltanserin. Psychiatry Res 2001;106:81-93.
239. 18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: Pharmacological studies. Nucl Med Biol 2001;28:271-279.
240. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, Staley JK, Garg PK, Seibyl JP, Innis RB. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160:1522-1524.
241. 18)F]deuteroaltanserin and PET. Psychiatry Res 2009;173:212-217.
242. Doble A, Girdlestone D, Piot O, Allam D, Betschart J, Boireau A, Dupuy A, Gueremy C, Menager J, Zundel JL, et al. Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist. Br J Pharmacol 1992;105:27-36.
243. 18F]RP 62203: A selective 5-HT2A receptor radioligand for positron emission tomography. Nucl Med Biol 1996;23:169-171.
244. Ashworth S, Hume SP, Lammertsma AA, Opacka-Juffry J, Shah F, Pike VW. Development of central 5-HT2A receptor radioligands for PET: Comparison of [3H]RP 62203 and [3H]SR 46349B kinetics in rat brain. Nucl Med Biol 1996;23:245-250.
245. Lopez-Gimenez JF, Vilaro MT, Palacios JM, Mengod G. [3H]MDL 100, 907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology 1998;37:1147-1158.
246. Kristiansen H, Elfving B, Plenge P, Pinborg LH, Gillings N, Knudsen GM. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse 2005;58:249-257.
247. 11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci 1996;58:187-192.
248. Johnson MP, Siegel BW, Carr AA. [3H]MDL 100, 907: A novel selective 5-HT2A receptor ligand. Naunyn Schmiedebergs Arch Pharmacol 1996;354:205-209.
249. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100, 907. Naunyn Schmiedebergs Arch Pharmacol 1997;356:446-454.
250. Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100, 907. J Nucl Med 1998;39:208-214.
251. 11C]MDL 100, 907. J Cereb Blood Flow Metab 2000;20:899-909.
252. 11)C]MDL 100, 907. J Cereb Blood Flow Metab 2007;27:161-172.
253. 11C]MDL 100, 907 PET and non-invasive kinetic analyses. Neuroimage 2010;50:984-993.
254. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 2008;42:306-314.
255. 18F]MHMZ. Bioorg Med Chem Lett 2008;18:1515-1519.
256. 18)F]MH.MZ. Nucl Med Biol 2009;36:447-454.
257. 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem 2009;17:2989-3002.
258. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging. Nucl Med Biol 2010;37:487-495.
259. 11C]Cimbi-5 as a 5-HT2A receptor agonist radioligand for positron emission tomography. J Nucl Med 2010;51:1763-1770.
260. 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur J Nucl Med Mol Imaging 2011;38:681-693.
261. Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: Comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 1995;115:622-628.
262. Kursar JD, Nelson DL, Wainscott DB, Baez M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol 1994;46:227-234.
263. Poissonnet G, Parmentier JG, Boutin JA, Goldstein S. The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications. Mini Rev Med Chem 2004;4:325-330.
264. Leonhardt S, Gorospe E, Hoffman BJ, Teitler M. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Mol Pharmacol 1992;42:328-335.
265. Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 1986;376:97-107.
266. Molineaux SM, Jessell TM, Axel R, Julius D. 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 1989;86:6793-6797.
267. Hemedah M, Coupar IM, Mitchelson FJ. [3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum. Br J Pharmacol 1999;126:179-188.
268. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-Pharmacological mechanisms. Pharmacol Ther 2010;125:169-179.
269. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-964.
270. Costall B, Naylor RJ. 5-HT3 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:27-37.
271. Fletcher S, Barnes NM. Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain. Brain Res 1996;729:281-284.
272. Abi-Dargham A, Laruelle M, Lipska B, Jaskiw GE, Wong DT, Robertson DW, Weinberger DR, Kleinman JE. Serotonin 5-HT3 receptors in schizophrenia: A postmortem study of the amygdala. Brain Res 1993;616:53-57.
273. Bufton KE, Steward LJ, Barber PC, Barnes NM. Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology 1993;32:1325-1331.
274. Parker RM, Barnes JM, Ge J, Barber PC, Barnes NM. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J Neurol Sci 1996;144:119-127.
275. Engleman EA, Rodd ZA, Bell RL, Murphy JM. The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy. CNS Neurol Disord Drug Targets 2008;7:454-467.
276. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-1843; quiz 1844.
277. 125I]DAIZAC), a selective high-affinity radioligand for 5-hydroxytryptamine3 receptors. J Pharmacol Exp Ther 1999;288:221-231.
278. 11C]MDL 72222, a potential 5-HT3 receptor radioligand: Distribution, kinetics and binding in the brain of the baboon. Neuropharmacology 1993;32:65-71.
279. 11C]YM060. Appl Radiat Isot 1995;46:907-910.
280. 11C]KF17643. Nucl Med Biol 1996;23:285-290.
281. 11C]-S21007 a novel 5HT3 partial agonist as a potential tracer for PET studies. J Labl Compd Radiopharm 1996;38:367-371.
282. 11C]S21007, a putative partial agonist for 5-HT3 receptors PET studies. Rat and primate in vivo biological evaluation. Life Sci 1998;62:115-129.
283. 18F]MR18445, a 5-HT3 receptor partial agonist. Bioorg Med Chem 1998;6:789-795.
284. Thorell JO, Stone-Elander S, Eriksson L, Ingvar M. N-Methylquipazine: Carbon-11 labelling of the 5-HT3 agonist and in vivo evaluation of its biodistribution using PET. Nucl Med Biol 1997;24:405-412.
285. Gao M, Wang M, Hutchins GD, Zheng QH. Synthesis of new carbon-11 labeled benzoxazole derivatives for PET imaging of 5-HT(3) receptor. Eur J Med Chem 2008;43:1570-1574.
286. Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:39-51.
287. Bonaventure P, Hall H, Gommeren W, Cras P, Langlois X, Jurzak M, Leysen JE. Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse 2000;36:35-46.
288. Jakeman LB, To ZP, Eglen RM, Wong EH, Bonhaus DW. Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1. Neuropharmacology 1994;33:1027-1038.
289. Waeber C, Sebben M, Grossman C, Javoy-Agid F, Bockaert J, Dumuis A. [3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain. Neuroreport 1993;4:1239-1242.
290. 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med 2009;50:900-908.
291. 11C]SB207145-PET. Neuroimage 2010;50:855-861.
292. 125I]SB207710, a potent, selective radioligand for 5-HT4 receptors. Br J Pharmacol 1993;110:10P.
293. Patel S, Roberts J, Moorman J, Reavill C. Localization of serotonin-4 receptors in the striatonigral pathway in rat brain. Neuroscience 1995;69:1159-1167.
294. Pike VW, Halldin C, Nobuhara K, Hiltunen J, Mulligan RS, Swahn CG, Karlsson P, Olsson H, Hume SP, Hirani E, Whalley J, Pilowsky LS, Larsson S, Schnell PO, Ell PJ, Farde L. Radioiodinated SB 207710 as a radioligand in vivo: Imaging of brain 5-HT4 receptors with SPET. Eur J Nucl Med Mol Imaging 2003;30:1520-1528.
295. 11C]SB207145 as the first in vivo serotonin 5-HT4 receptor radioligand for PET imaging in man. Curr Radiopharm 2008;1:110-114.
296. 11C]SB207145 in the Gottingen minipig. J Cereb Blood Flow Metab 2009;29:186-196.
297. Volk B, Nagy BJ, Vas S, Kostyalik D, Simig G, Bagdy G. Medicinal chemistry of 5-HT5A receptor ligands: A receptor subtype with unique therapeutical potential. Curr Topics Med Chem 2010;10:554-578.
298. Gannon RL, Peglion JL, Millan MJ. Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: Interaction studies with citalopram. Eur Neuropsychopharmacol 2009;19:887-897.
299. Grailhe R, Grabtree GW, Hen R. Human 5-HT(5) receptors: The 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol 2001;418:157-167.
300. Nelson DL. 5-HT5 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:53-58.
301. Woolley ML, Marsden CA, Fone KC. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:59-79.
302. 125I]SB-258585. Synapse 2002;45:191-199.
303. 125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol 2000;130:1597-1605.
304. Zhou P, Yan Y, Bernotas R, Harrison BL, Huryn D, Robichaud AJ, Zhang GM, Smith DL, Schechter LE. 4-(2-Aminoethoxy)-N-(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands. Bioorg Med Chem Lett 2005;15:1393-1396.
305. 18F]12ST05 as a potential 5-HT6 PET radioligand. Nucl Med Biol 2007;34:995-1002.
306. 11C]GSK215083 as potential PET radioligand for the 5-HT6 receptor in porcine brain. J Cereb Blood Flow Metab 2005;25:S598.
307. 11C]GSK224558 as a potential PET ligand for the delineation of 5-HT6 receptors. Neuroimage 2006;31:T12-T43.
308. 11C]GSK215083 in human. Neuroimage 2008;41:T20.
309. 11C]GSK215083, in papio anubis. Neuroimage 2010;52:S37.
310. Thomas DR, Atkinson PJ, Hastie PG, Roberts JC, Middlemiss DN, Price GW. [3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues. Neuropharmacology 2002;42:74-81.
311. Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 2004;25:481-486.
312. Thomas DR, Hagan JJ. 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:81-90.
313. Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO. The cloned human 5-HT7 receptor splice variants: A comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol 2001;363:620-632.
314. Andries J, Lemoine L, Mouchel-Blaisot A, Tang S, Verdurand M, Le Bars D, Zimmer L, Billard T. Looking for a 5-HT7 radiotracer for positron emission tomography. Bioorg Med Chem Lett 2010;20:3730-3733.
315. Kikuchi C, Hiranuma T, Koyama M. Tetrahydrothienopyridylbutyl-tetrahydrobenzindoles: New selective ligands of the 5-HT7 receptor. Bioorg Med Chem Lett 2002;12:2549-2552.
316. 11C]DR4446. J Labl Compd Radiopharm 2002;45:857-866.
317. Palacin M, Estevez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev 1998;78:969-1054.
318. Murphy DL, Lesch KP. Targeting the murine serotonin transporter: Insights into human neurobiology. Nat Rev Neurosci 2008;9:85-96.
319. Huang Y, Zheng MQ, Gerdes JM. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr Topics Med Chem 2010;10:1499-1526.
320. 3H]paroxetine binding sites in suicide brains. J Neural Transm 1997;104:921-929.
321. 11C]venlafaxine: Serotonin uptake inhibition, biodistribution and binding in living pig brain. Eur Neuropsychopharmacol 1997;7:195-200.
322. Stanley M, Virgilio J, Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 1982;216:1337-1339.
323. 11C]cyanoimipramine. Int J Rad Appl Instrum B 1987;14:587-592.
324. 123I]beta-CIT: Pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
325. 123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 1993;94:137-146.
326. 11C]beta-CIT labelled in two different positions. Nucl Med Biol 1999;26:343-350.
327. Bergstrom KA, Halldin C, Hall H, Lundkvist C, Ginovart N, Swahn CG, Farde L. In vitro and in vivo characterisation of nor-beta-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med 1997;24:596-601.
328. Hiltunen J, Akerman KK, Kuikka JT, Bergstrom KA, Halldin C, Nikula T, Rasanen P, Tiihonen J, Vauhkonen M, Karhu J, Kupila J, Lansimies E, Farde L. Iodine-123 labeled nor-beta-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. Eur J Nucl Med 1998;25:19-23.
329. Reneman L, Booij J, Lavalaye J, De Bruin K, De Wolff FA, Koopmans RP, Stoof JC, Den Heeten GJ. Comparative in vivo study of iodine-123-labeled beta-CIT and nor-beta-CIT binding to serotonin transporters in rat brain. Synapse 1999;34:77-80.
330. 123I]nor-beta-CIT in atypical depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1251-1255.
331. 123)I] nor-beta-CIT SPECT imaging. Psychiatry Res 2007;154:125-131.
332. Maron E, Kuikka JT, Ulst K, Tiihonen J, Vasar V, Shlik J. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci 2004;254:392-396.
333. Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, Zettinig G, Hornik K, Pirker W, Thau K. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 2008;33:3126-3134.
334. Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res 2004;132:173-181.
335. 123)I]beta-CIT SPECT study. J Neural Transm 2008;115:721-729.
336. 123)I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur J Nucl Med 1999;26:844-853.
337. 123I]IDAM, 5-iodo-2-((2-((dimethylamino)-methyl)phenyl)thio)benzyl alcohol. J Med Chem 1999;42:333-335.
338. 123)I]IDAM. Eur J Nucl Med 1999;26:854-861.
339. 123)I]ODAM. Eur J Nucl Med 1999;26:1359-1362.
340. 123)I-ADAM: A serotonin transporter imaging agent. J Nucl Med 2004;45:834-841.
341. 123I-ADAM brain SPECT in healthy non-human primates. Nucl Med Commun 2004;25:515-519.
342. 123I-ADAM: Optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med 2005;46:1301-1309.
343. 123I-ADAM for SPECT studies on humans. J Nucl Med 2008;49:247-254.
344. 123I]ADAM: A SPECT validation study. Eur J Nucl Med Mol Imaging 2005;32:1329-1336.
345. 123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology 2006;188:263-272.
346. 123I]-ADAM. J Neural Transm 2006;113:659-670.
347. 123I-ADAM SPECT study. Psychopharmacology 2006;189:145-153.
348. 123I]ADAM SPECT study. Psychopharmacology 2007;191:333-339.
349. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: A preliminary study. J Nucl Med 2005;46:973-977.
350. Schuh-Hofer S, Richter M, Geworski L, Villringer A, Israel H, Wenzel R, Munz DL, Arnold G. Increased serotonin transporter availability in the brainstem of migraineurs. J Neurol 2007;254:789-796.
351. 123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. J Psychiatry Neurosci 2007;32:234-240.
352. 123)I-ADAM SPECT imaging of serotonin transporter binding in patients with Night Eating Syndrome: A preliminary report. Psychiatry Res 2008;162:214-220.
353. 11C](+)McN5652. Synapse 1995;20:37-43.
354. 11C-McN 5652 in healthy humans. J Nucl Med 2004;45:682-694.
355. 11C](+)McN5652-PET and the multi-linear reference tissue model: Loss of transporters or artifact of tracer kinetic modelling? J Psychopharmacol 2007;21:628-634.
356. 11C]DASB. Neuropsychopharmacology 2005;30:1741-1750.
357. 11C]McN 5652. Am J Psychiatry 2005;162:915-923.
358. Miller JM, Kinnally EL, Ogden RT, Oquendo MA, Mann JJ, Parsey RV. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synapse 2009;63:565-573.
359. 18F]fluoromethyl)-(+)-McN5652. Neuropsychopharmacology 2003;28:2010-2019.
360. 11C]AFM. J Cereb Blood Flow Metab 2002;22:1377-1398.
361. 18)F-ADAM): An improved PET radioligand for serotonin transporters. J Nucl Med 2003;44:1890-1897.
362. 18F]-ADAM) as a serotonin transporter imaging agent. Appl Radiat Isot 2004;61:1247-1254.
363. 11C]SMe-ADAM, an imaging agent for the brain serotonin transporter: Synthesis, pharmacological characterization and microPET studies in rats. Nucl Med Biol 2006;33:53-63.
364. 11C]DAPA). Nucl Med Biol 2002;29:741-751.
365. 11C]AFA). Nucl Med Biol 2004;31:727-738.
366. Jarkas N, McConathy J, Votaw JR, Voll RJ, Malveaux E, Camp VM, Williams L, Goodman RR, Kilts CD, Goodman MM. Synthesis and characterization of EADAM: A selective radioligand for mapping the brain serotonin transporters by positron emission tomography. Nucl Med Biol 2005;32:75-86.
367. 11C]DASB. Eur J Nucl Med 2000;27:1719-1722.
368. 11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl Med Biol 2004;31:983-994.
369. 11)C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse 2005;58:173-183.
370. 11C]-DASB: A probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 2002;29:509-515.
371. Wilson AA, Houle S. Radiosynthesis of carbon-11 labelled N-methyl-2-(arylthio)benzylamines: Potential radiotracers for the serotonin reuptake receptor. J Labl Compd Radiopharm 1999;42:1277-1288.
372. 11)C]-DASB binding to the human serotonin transporter: Modeling strategies. J Cereb Blood Flow Metab 2001;21:1342-1353.
373. 11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 2002;43:678-692.
374. 11C]DASB: Test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med 2006;47:208-214.
375. 11C]DASB and positron emission tomography. Biol Psychiatry 2006;59:821-828.
376. Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, Tanada S, Suhara T. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology 2006;185:395-399.
377. 11C]DASB positron emission tomography. Psychopharmacology 2007;193:539-545.
378. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, Kennedy J, Wilson AA. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: Effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004;61:1271-1279.
379. 11C]DASB. Am J Psychiatry 2007;164:1858-1865.
380. 11)C]DASB PET study. Mol Psychiatry 2008;13:606-613.
381. 11C]DASB. Biol Psychiatry 2005;57:1510-1516.
382. 11C]DASB PET study. J Neural Transm 2007;114:1603-1609.
383. 11C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol Clin Exp Res 2007;31:28-32.
384. 11C]DASB and positron emission tomography. Biol Psychiatry 2006;60:207-217.
385. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, Hashemi SH, Baare WF, Madsen J, Hasselbalch SG, Kringelbach ML, Mortensen EL, Knudsen GM. The personality trait openness is related to cerebral 5-HTT levels. Neuroimage 2009;45:280-285.
386. Kalbitzer J, Erritzoe D, Holst KK, Nielsen FA, Marner L, Lehel S, Arentzen T, Jernigan TL, Knudsen GM. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry 2010;67:1033-1039.
387. Frokjaer VG, Vinberg M, Erritzoe D, Svarer C, Baare W, Budtz-Joergensen E, Madsen K, Madsen J, Kessing LV, Knudsen GM. High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage 2009;46:360-366.
388. 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med 2005;46:1505-1515.
389. Chalon S, Tarkiainen J, Garreau L, Hall H, Emond P, Vercouillie J, Farde L, Dasse P, Varnas K, Besnard JC, Halldin C, Guilloteau D. Pharmacological characterization of N, N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity. J Pharmacol Exp Ther 2003;304:81-87.
390. Cortes R, Soriano E, Pazos A, Probst A, Palacios JM. Autoradiography of antidepressant binding sites in the human brain: Localization using [3H]imipramine and [3H]paroxetine. Neuroscience 1988;27:473-496.
391. Plenge P, Mellerup ET, Laursen H. Regional distribution of the serotonin transport complex in human brain, identified with 3H-paroxetine, 3H-citalopram and 3H-imipramine. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:61-72.
392. 11C]MADAM: A test-retest reproducibility study. Synapse 2006;60:256-263.
393. Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L. PET measurement of serotonin transporter occupancy: A comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 2007;10:777-785.
394. Henningsson S, Borg J, Lundberg J, Bah J, Lindstrom M, Ryding E, Jovanovic H, Saijo T, Inoue M, Rosen I, Traskman-Bendz L, Farde L, Eriksson E. Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men. Biol Psychiatry 2009;66:477-485.
395. Jovanovic H, Lundberg J, Karlsson P, Cerin A, Saijo T, Varrone A, Halldin C, Nordstrom AL. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 2008;39:1408-1419.
396. 11)C] MADAM PET. Psychiatry Res 2009;172:31-37.
397. Lundberg J, Borg J, Halldin C, Farde L. A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain. Psychopharmacology 2007;195:425-433.
398. 18)F]-ADAM) for imaging serotonin transporters. Appl Radiat Isot 2008;66:625-631.
399. 18]-ADAM, a potent serotonin transporter imaging agent. Appl Radiat Isot 2009;67:1063-1067.
400. 18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography. Neuroimage 2009;45:687-693.
401. 18F]-ADAM in rats and monkeys. Eur J Nucl Med Mol Imaging 2010;37:545-555.
402. Diksic M, Young SN. Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan. J Neurochem 2001;78:1185-1200.
403. Cohen Z, Tsuiki K, Takada A, Beaudet A, Diksic M, Hamel E. In-vivo synthesized radioactively labeled alpha-methyl serotonin as a selective tracer for visualization of brain-serotonin neurons. Synapse 1995;21:21-28.
404. Diksic M, Nagahiro S, Sourkes TL, Yamamoto YL. A new method to measure brain-serotonin synthesis in vivo 1. Theory and basic data for a biological model. J Cereb Blood Flow Metab 1990;10:1-12.
405. 11]alpha-methyl-L-tryptophan and positron emission tomography compared to CSF 5-hydroxyindole-3-acetic acid concentrations. Neuropsychopharmacology 1998;19:345-353.
406. 11)]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate in vivo. J Cereb Blood Flow Metab 1997;17:659-669.
407. 11]methyl-L-tryptophan. Synapse 1998;28:33-43.
408. Gharib A, Balende C, Sarda N, Weissmann D, Plenevaux A, Luxen A, Bobillier P, Pujol JF. Biochemical and autoradiographic measurements of brain serotonin synthesis rate in the freely moving rat: A reexamination of the alpha-methyl-L-tryptophan method. J Neurochem 1999;72:2593-2600.
409. 11] and [C-14] labeled tracer. J Cereb Blood Flow Metab 2000;20:244-252.
410. 11]methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism. J Cereb Blood Flow Metab 2000;20:2-9.
411. Perreau-Linck E, Beauregard M, Gravel P, Paquette V, Soucy JP, Diksic M, Benkelfat C. In vivo measurements of brain trapping of C-11-labelled alpha-methyl-L-tryptophan during acute changes in mood states. J Psychiatr Neurosci 2007;32:430-434.
412. 11]methyl-L-tryptophan PET study. Neurochem Int 2008;52:701-708.
413. Bjurling P, Watanabe Y, Tokushige M, Oda T, Langstrom B. Syntheses of beta-C-11-labeled L-tryptophan and 5-hydroxy-L-tryptophan using a multi-enzymatic reaction route. J Chem Soc Perkin Trans 1989;1:1331-1334.
414. Hartvig P, Tedroff J, Lindner KJ, Bjurling P, Chang CW, Tsukada H, Watanabe Y, Langstrom B. Positron emission tomographic studies on aromatic L-amino-acid decarboxylase activity in-vivo for L-dopa and 5-hydroxy-L-tryptophan in the monkey brain. J Neural Transm 1993;94:127-135.
415. Hartvig P, Lindner KJ, Bjurling P, Langstrom B, Tedroff J. Pyridoxine effect on synthesis rate of serotonin in the monkey brain measured with positron emission tomography. J Neural Transm 1995;102:91-97.
416. 11]5-hydroxytryptophan in human brain studied by positron emission tomography. Psychiatry Res Neuroimaging 1992;45:215-225.
417. 11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. J Cereb Blood Flow Metab 2002;22:1352-1366.
418. 11]5-hydroxytryptophan accumulation. Int J Neuropsychopharmacol 2005;8:633-634.
419. 11]methyl-L-tryptophan for positron emission tomography imaging of serotonin synthesis capacity in the rhesus monkey brain. J Cereb Blood Flow Metab 2007;27:821-830.